Literature DB >> 18324354

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

Hideho Okada1, Keri L Low, Gary Kohanbash, Heather A McDonald, Ronald L Hamilton, Ian F Pollack.   

Abstract

We investigated the protein expression of three glioma-associated antigens (GAAs) in pediatric brain stem glioma (BSG) and non-brain stem glioma (NBSG) cases with a view to their possible use in immunotherapy. Expression of EphA2, IL-13Ralpha2 and Survivin were studied by immunohistochemistry on paraffin-embedded tissues using a series of 15 BSG cases and 12 NBSG cases. Thirteen of 15 BSGs and all 12 NBSGs expressed at least one of GAAs; and 7 BSGs and 9 NBSGs expressed at least two of these GAAs at higher levels than non-neoplastic brain. There was no association between the tumor grade and levels of GAA expression. Although many cases demonstrated diffuse expression of GAAs throughout specimens, partial or patchy expression was noted in a small number of cases, suggesting a need for targeting multiple GAAs in immunotherapy. These results suggest that EphA2, IL-13Ralpha2 and Survivin are suitable targets for developing vaccine strategies for pediatric glioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324354      PMCID: PMC2561297          DOI: 10.1007/s11060-008-9566-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

1.  Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.

Authors:  Masaki Uematsu; Ikuroh Ohsawa; Toshiyuki Aokage; Kiyomi Nishimaki; Kouji Matsumoto; Hiroshi Takahashi; Sadamitsu Asoh; Akira Teramoto; Shigeo Ohta
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

2.  Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.

Authors:  W Debinski; D M Gibo
Journal:  Mol Med       Date:  2000-05       Impact factor: 6.354

3.  Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

Authors:  K M Giezeman-Smits; H Okada; C S Brissette-Storkus; L A Villa; J Attanucci; M T Lotze; I F Pollack; M E Bozik; W H Chambers
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

4.  Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.

Authors:  Kerstin Otto; Mads Hald Andersen; Andreas Eggert; Petra Keikavoussi; Lars Østergaard Pedersen; Jörg C Rath; Markus Böck; Eva-B Bröcker; Per Thor Straten; Eckhart Kämpgen; Jürgen C Becker
Journal:  Vaccine       Date:  2005-01-04       Impact factor: 3.641

5.  Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

Authors:  Junichi Eguchi; Manabu Hatano; Fumihiko Nishimura; Xinmei Zhu; Jill E Dusak; Hidemitsu Sato; Ian F Pollack; Walter J Storkus; Hideho Okada
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

Authors:  Fumiyoshi Okano; Walter J Storkus; William H Chambers; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

7.  Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group.

Authors:  A L Albright; R J Packer; R Zimmerman; L B Rorke; J Boyett; G D Hammond
Journal:  Neurosurgery       Date:  1993-12       Impact factor: 4.654

8.  Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.

Authors:  H Okada; H Tahara; M R Shurin; J Attanucci; K M Giezeman-Smits; W K Fellows; M T Lotze; W H Chambers; M E Bozik
Journal:  Int J Cancer       Date:  1998-10-05       Impact factor: 7.396

9.  Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.

Authors:  Hideho Okada; Frank S Lieberman; Howard D Edington; Timothy F Witham; Mark J Wargo; Quan Cai; Elaine H Elder; Theresa L Whiteside; S Clifford Schold; Ian F Pollack
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

10.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

View more
  46 in total

1.  Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma.

Authors:  Alberto Broniscer; Justin N Baker; Suzanne J Baker; Susan N Chi; J Russell Geyer; E Brannon Morris; Amar Gajjar
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

Review 2.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

3.  Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Authors:  Marianela Candolfi; Weidong Xiong; Kader Yagiz; Chunyan Liu; A K M G Muhammad; Mariana Puntel; David Foulad; Ali Zadmehr; Gabrielle E Ahlzadeh; Kurt M Kroeger; Matthew Tesarfreund; Sharon Lee; Waldemar Debinski; Dhruv Sareen; Clive N Svendsen; Ron Rodriguez; Pedro R Lowenstein; Maria G Castro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

Review 4.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

5.  Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

Authors:  Giedre Krenciute; Simone Krebs; David Torres; Meng-Fen Wu; Hao Liu; Gianpietro Dotti; Xiao-Nan Li; Maciej S Lesniak; Irina V Balyasnikova; Stephen Gottschalk
Journal:  Mol Ther       Date:  2015-10-30       Impact factor: 11.454

Review 6.  Vaccination strategies for neuro-oncology.

Authors:  John H Sampson; Duane A Mitchell
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

7.  Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Ronald L Hamilton; Ashok Panigrahy; Daniel P Normolle; Angela K Connelly; Sharon Dibridge; Gary Mason; Theresa L Whiteside; Hideho Okada
Journal:  J Neurooncol       Date:  2016-09-13       Impact factor: 4.130

Review 8.  Gene therapy for brain tumors: basic developments and clinical implementation.

Authors:  Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

9.  Gliomas in children.

Authors:  Jane E Minturn; Michael J Fisher
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Tumour vaccine approaches for CNS malignancies: progress to date.

Authors:  Johnathan D Ebben; Brandon G Rocque; John S Kuo
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.